Analysis and policy recommendations on the accountability at the EMA

Since the COVID-19 crisis has started, we have seen governments pressuring their own regulatory agencies to speed up the process of marketing authorisation. To make sure that this marketing authorisation process is done independently and transparently, the concept of accountability is key. Over the last year Wemos has conducted a qualitative analysis on the concept of accountability at the European Medicines Agency (EMA) and the perception hereof for different stakeholders in the process of marketing authorisation. Additionally, Wemos has looked into the risk of bias in Pre-Submission Activities (PSAs). This analysis lead to several policy recommendations in order to improve EMA’s accountability and to have better safeguards regarding risk of bias in PSAs.

The EMA plays a central role in the approval of new pharmaceutical products within the European Union. Because of its important role in marketing authorisation of new pharmaceutical products, numerous measures are taken to attain the highest standards. Despite all the policies that the EMA  puts in place to safeguard independent decision making, several cases have been identified that raised concerns regarding the approval process. These cases lead to Wemos investigating how the EMA copes with the concept of accountability and stakeholders involved in medicine evaluation perceive accountability.

Several stakeholders mentioned that ad-hoc experts are potentially useful in increasing the performance accountability of the EMA, but that more transparency is required in the selection criteria of these experts. Moreover, there is not always a clear separation between those who provide pharmaceutical companies scientific advice and those who are involved in the assessment of new pharmaceutical products. This could lead to an increased risk of bias. These risks could potentially be extended to national regulatory authorities. If you are interested in more highlights of our findings and policy recommendations please check out our 4-pager: ‘Accountability at the EMA and Risk of Bias in Pre-submission Activities at the EMA’.

Read Wemos’ intern Eunjin Jang’s thesis: ‘Accountability of the European Medicines Agency in Marketing Authorisation of New Medicines’

Photo: by Pexels via Pixabay

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

Our highlights of 2021: seizing momentum for global health

03-01-2022

We want everyone, everywhere to receive the health care services they need without suffering financial hardship. The path to achieving that goal is far from paved. However, in 2021 we have seen – and taken – opportunities to push for the structural changes that we envision. We are proud to present our highlights of 2021! 

Continue reading

New coalition agreement: this is what a Dutch Global Health Strategy should look like

21-12-2021

The Covid-19 pandemic has strengthened calls for the need for a coherent Dutch Global Health Strategy. Wemos – as one of the founding members of the Dutch Global Health Alliance (DGHA) – is therefore thrilled to see that the Dutch government has included the intention to develop such a Strategy in the new coalition agreement ‘Omzien naar elkaar, vooruitkijken naar de toekomst’. As the Dutch Global Health Alliance, we have a clear position on the topic. Earlier this month, we shared our views in a policy brief that we submitted to the Advisory Council on International Affairs (AIV).

Continue reading